Unknown

Dataset Information

0

Functional characterization of an isoform-selective inhibitor of PI3K-p110? as a potential anticancer agent.


ABSTRACT: Genetic approaches have shown that the p110? isoform of class Ia phosphatidylinositol-3-kinase (PI3K) is essential for the growth of PTEN-null tumors. Thus, it is desirable to develop p110?-specific inhibitors for cancer therapy. Using a panel of PI3K isoform-specific cellular assays, we screened a collection of compounds possessing activities against kinases in the PI3K superfamily and identified a potent and selective p110? inhibitor: KIN-193. We show that KIN-193 is efficacious specifically in blocking AKT signaling and tumor growth that are dependent on p110? activation or PTEN loss. Broad profiling across a panel of 422 human tumor cell lines shows that the PTEN mutation status of cancer cells strongly correlates with their response to KIN-193. Together, our data provide the first pharmacologic evidence that PTEN-deficient tumors are dependent on p110? in animals and suggest that KIN-193 can be pursued as a drug to treat tumors that are dependent on p110? while sparing other PI3K isoforms.We report the first functional characterization of a p110?-selective inhibitor, KIN-193, that is efficacious as an antitumor agent in mice. We show that this class of inhibitor holds great promise as a pharmacologic agent that could be used to address the potential therapeutic benefit of treating p110?-dependent PTEN-deficient human tumors.

SUBMITTER: Ni J 

PROVIDER: S-EPMC3384541 | biostudies-literature | 2012 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Functional characterization of an isoform-selective inhibitor of PI3K-p110β as a potential anticancer agent.

Ni Jing J   Liu Qingsong Q   Xie Shaozhen S   Carlson Coby C   Von Thanh T   Vogel Kurt K   Riddle Steve S   Benes Cyril C   Eck Michael M   Roberts Thomas T   Gray Nathanael N   Zhao Jean J  

Cancer discovery 20120412 5


<h4>Unlabelled</h4>Genetic approaches have shown that the p110β isoform of class Ia phosphatidylinositol-3-kinase (PI3K) is essential for the growth of PTEN-null tumors. Thus, it is desirable to develop p110β-specific inhibitors for cancer therapy. Using a panel of PI3K isoform-specific cellular assays, we screened a collection of compounds possessing activities against kinases in the PI3K superfamily and identified a potent and selective p110β inhibitor: KIN-193. We show that KIN-193 is efficac  ...[more]

Similar Datasets

| S-EPMC3902650 | biostudies-literature
| S-EPMC3328000 | biostudies-literature
| S-EPMC7962815 | biostudies-literature
| S-EPMC10246239 | biostudies-literature
| S-EPMC5927520 | biostudies-literature
2023-11-01 | GSE242387 | GEO
| S-EPMC2720137 | biostudies-literature
| S-EPMC10093441 | biostudies-literature
| S-EPMC4648175 | biostudies-other
| S-EPMC6301802 | biostudies-literature